Welcome to our dedicated page for Sanofi FR news (Ticker: SNY), a resource for investors and traders seeking the latest updates and insights on Sanofi FR stock.
Sanofi reports news as a global biopharmaceutical issuer with American depositary shares traded under SNY. Company updates center on medicines and vaccines built around immunology, specialty care, rare diseases, diabetes, respiratory disease and infectious-disease prevention, including recurring developments for products such as Dupixent, BEYFORTUS, insulins and pipeline candidates.
Sanofi news also covers clinical and regulatory milestones, collaborations with biotechnology and diagnostics partners, patient-access programs, community health initiatives, leadership changes and capital-allocation actions. As a foreign issuer, updates may reflect both parent-company announcements and ADR-related public-company disclosures.
Sanofi and the Parkinson's Foundation are collaborating to enhance genetic testing and counseling for Parkinson's disease patients in the U.S. Over two years, Sanofi will invest $1 million in the PD GENEration: Mapping the Future of Parkinson's Disease initiative. The study aims to improve understanding of genetic mutations related to Parkinson's, facilitating patient access to clinical trials. Initial results show a higher prevalence of genetic links to the disease, with plans to enroll 15,000 participants.
Sanofi Genzyme announced the presentation of new data from its neurology portfolio at MSVirtual2020, taking place from September 11-13, 2020. The event will showcase findings related to tolebrutinib (SAR442168), a selective BTK inhibitor aiming to address neuroinflammation in multiple sclerosis (MS). Key presentations will focus on the efficacy and safety of AUBAGIO® and LEMTRADA®, emphasizing their positive clinical profiles. Notable presentations include the effects of teriflunomide on pediatric MS patients and the long-term safety of alemtuzumab.
Sanofi reported its Q2 2020 results with net sales of €8,207 million, down 4.9% year-over-year. Specialty Care sales grew by 17.4%, primarily fueled by Dupixent®, which saw a 70% increase to €858 million. However, COVID-19 impacted sales in Vaccines and General Medicines, with declines of 6.8% and 12.7%, respectively. Business net income rose 3.6% to €1,601 million, while business EPS increased to €1.28. Sanofi revised its full-year 2020 business EPS guidance up to 6%-7%. Key regulatory advancements include Dupixent® approvals in China and for children in the U.S.
Sanofi and The University of Texas MD Anderson Cancer Center announced a five-year strategic collaboration on July 14, 2020, aimed at accelerating the development of cancer treatments. This alliance merges MD Anderson's clinical trial capabilities with Sanofi's investigational drug pipeline, focusing on biomarker-driven studies. The collaboration seeks to optimize patient selection and identify effective therapy combinations, thereby enhancing treatment outcomes for challenging cancers. Initial projects are expected to commence in summer 2020.
Kymera Therapeutics has formed a strategic collaboration with Sanofi (NASDAQ: SNY) to develop therapies targeting IRAK4 for immune-inflammatory diseases. The deal includes a $150 million upfront payment and potential milestones exceeding $2 billion. Kymera retains rights to its IRAK4 program in oncology and can participate in US development. IRAK4 is implicated in several inflammatory conditions, and preclinical studies show promising results. The partnership aims to leverage Sanofi's drug development expertise to enhance patient outcomes.
Sanofi and Sobi, alongside the World Federation of Hemophilia, have announced a further donation of up to 500 million IUs of factor therapy to the WFH Humanitarian Aid Program, completing their 2014 pledge to donate up to 1 billion IUs over ten years. Since 2015, the companies have donated over 450 million IUs, benefiting over 17,200 patients in 42 countries. This initiative aims to enhance treatment accessibility for hemophilia patients in developing regions, where more than 75% lack proper care.